Skip to content

Gilead a buy ahead of earnings: Baird

July 13, 2017

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) ahead of earningsand believes that U.S. Hep C Rx data implies flat sequential sales and he believes WW Hep C sales could beat consensus by 10%.

The analyst stated “with HIV seeing steady conversions from TDF- to TAF-based regimens, we believe operating results could provide some much needed stability, resulting in some upside to the stock from these levels”.

No change to the price target of $87.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: